Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)

What Was Tested

The trial (phase 2) is built around NAD+.

This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent.

It had two arms (groups): one (experimental) and one (experimental).

The registry classes the interventions as drug.

More on the Plan

This is an open label, Phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent.

Ten subjects will be accrued in this protocol in two cohorts.

The two cohorts can enroll concurrently.

Study visits will be every 90 days.

Who Took Part

The registry lists 10 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Subject must voluntarily sign and date an informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any research directed procedures. Stated willingness to comply with all study procedures and be available for the duration of the study. Be a male or female aged ≥ 18 years of age. Subject must have confirmation of high risk CCUS (defined by CHRS score) or the diagnosis of MDS in the lower risk category as defined by IPSS-M less than 0. Patients must have ECOG of ≤ 2.

The full record lists 12 inclusion and 15 exclusion criteria; among the exclusions: subject is known to be positive for hiv with uncontrolled disease. hiv testing is not required; renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia; subject has a history of other malignancies prior to study entry, with the exception of:.

How the Study Was Run

Design: non-randomized, parallel-group and open-label.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label NAD+ study: the participants and staff both knew the treatment.

It started in 2026-05-20 with completion listed for 2029-12-18.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 3 secondary outcomes, for example Safety Information Collection.

What This Means in Plain Language

Put simply, this is a phase 2, non-randomized trial of NAD+ in 10 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.